From OHC, Specialists in the Treatment of Adult Cancers and Blood Disorders

May 6, 2020

The cancer experts at OHC are giving hope to women with ovarian cancer with the evaluation of a new treatment that looks to inhibit the growth of ovarian cancer cells. OHC is the only healthcare provider in Ohio to offer this through its nationally-recognized clinical trials program.

Treatment of ovarian cancer can be difficult because it can easily go undetected until it has spread to other parts of the abdomen. At this late stage, ovarian cancer is more difficult to treat and can be fatal. That’s why OHC is bringing important new treatments to the region and giving women hope against this deadly cancer.

“Ovarian cancer is challenging primarily for two reasons,” says OHC’s Cynthia C. Chua, MD, medical oncologist and hematologist who serves as the principal investigator for gynecologic cancer clinical trials at OHC. “First, there are no screening tests available for ovarian cancer like the Pap test we have for cervical cancer. Second, ovarian cancer often has no symptoms in the early stages. Later stages are associated with symptoms, but they can be non-specific, such as loss of appetite and weight loss. So, about 80 percent of all cases are found later. By offering this clinical trial, OHC is hopeful we can find a new and promising treatment for patients that can help during later stages, when most ovarian cancers are diagnosed.”

Another reason why ovarian cancer remains a deadly malignancy is because most patients’ cancer returns and is resistant to platinum-containing chemotherapy.

“There currently is no second-line chemotherapy treatment for patients whose cancer did not respond to the first round of chemotherapy,” Dr. Chua explained. “In this trial, we are evaluating the drug, mirvetuximab soravtansine, to determine if it will stop the growth of the cancer. It has shown promising results on tumors with folate receptors, which most ovarian tumors have.”

The drug will also be evaluated for treatment of primary peritoneal and fallopian tube cancer, whose tumors also express a high-level of folate receptors.

Dr. Chua works closely with OHC’s team of nationally-recognized gynecologic oncologists, Dené C. Wrenn, MD, Marcia C. Bowling, MD, and Ajit Gubbi, DO. Together, with OHC’s radiation oncologists and cancer genetic specialists, the team is advancing the treatment of gynecologic cancers, so women can beat their disease and return to their normal lives.

“This is an example of why patients should always ask their doctor if a clinical trial is available for their type of cancer. The drug OHC is evaluating for ovarian cancer could show remarkable results, and the only women who will benefit from it right now will be those enrolled in the trial.” Dr. Chua added. “At OHC, we understand that whenever a better cancer treatment is discovered, it’s always in a clinical trial.”

To learn more about this and other clinical trials at OHC, or for a second opinion, contact OHC at 1-888-649-4800 or click here.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *